PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 18068103-2 2008 A selective inhibitor of ERK1/2 pathway, PD98059 and a selective inhibitor of p38MAPK, SB203580 each alone significantly reversed the IL-1-induced growth inhibition of A375-6 cells. SB 203580 87-95 interleukin 1 alpha Homo sapiens 134-138 21663740-6 2011 In the presence of both U0126 and SB203580, cytotrienin A inhibited TNF-alpha- and IL-1alpha-induced ICAM-1 expression at almost equivalent concentrations. SB 203580 34-42 interleukin 1 alpha Homo sapiens 83-92 18292576-8 2008 SB203580 inhibited the phosphorylation of c-Fos enhanced by IL-1 plus IL-6, and diminished expression of the CRP gene. SB 203580 0-8 interleukin 1 alpha Homo sapiens 60-64 22675954-7 2012 The increase of IL-8 stimulated by IL-1alpha or TNF-alpha was also suppressed by treatment with U0126 or SB203580. SB 203580 105-113 interleukin 1 alpha Homo sapiens 35-44 18068103-3 2008 Co-treatment with PD98059 and SB203580 completely reversed the IL-1-induced growth inhibition. SB 203580 30-38 interleukin 1 alpha Homo sapiens 63-67 16532021-6 2006 The p38 inhibitor SB203580 and the PKC inhibitors Calphostin C and Go6976 completely inhibited IL-1-induced IL-6 production. SB 203580 18-26 interleukin 1 alpha Homo sapiens 95-99 16953813-3 2006 OBJECTIVES: The purpose of this study was to investigate the caseinolytic activity in human osteosarcoma cell line U2OS cells stimulated with interleukin-1alpha (IL-1alpha) or Porphyromonas gingivalis in the absence or presence of p38 inhibitor SB203580, mitogen-activated protein kinase kinase (MEK) inhibitor U0126, and phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002. SB 203580 245-253 interleukin 1 alpha Homo sapiens 142-160 16953813-3 2006 OBJECTIVES: The purpose of this study was to investigate the caseinolytic activity in human osteosarcoma cell line U2OS cells stimulated with interleukin-1alpha (IL-1alpha) or Porphyromonas gingivalis in the absence or presence of p38 inhibitor SB203580, mitogen-activated protein kinase kinase (MEK) inhibitor U0126, and phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002. SB 203580 245-253 interleukin 1 alpha Homo sapiens 162-171 16953813-8 2006 From the results of casein zymography and ELISA, SB203580, U0126, and LY294002 significantly reduced the IL-1alpha or P. gingivalis-stimulated t-PA production, respectively (p < 0.05). SB 203580 49-57 interleukin 1 alpha Homo sapiens 105-114 16410064-8 2006 From the results of casein zymography and ELISA, SB203580, U0126, and LY294002 significantly reduced the IL-1alpha-stimulated t-PA production, respectively (p < 0.05). SB 203580 49-57 interleukin 1 alpha Homo sapiens 105-114 15102045-3 2004 OBJECTIVES: The purpose of this study was to investigate the gelatinolytic activity in human osteosarcoma cells stimulated with interleukin-1alpha (IL-1alpha) or Porphyromonas gingivalis in the absence or presence of SB203580 (p38 inhibitor), U0126 [mitogen-activated protein kinase kinase (MEK) inhibitor], and LY294002 [phosphatidylinositaol 3-kinase (PI3K) inhibitor]. SB 203580 217-225 interleukin 1 alpha Homo sapiens 128-146 15735656-9 2005 This IL-1alpha-induced GM-CSF mRNA stability was prevented by either dexamethasone or the p38(MAPK) inhibitor, SB203580, neither of which influenced GM-CSF mRNA stability in thrombin-treated cells. SB 203580 111-119 interleukin 1 alpha Homo sapiens 5-14 15102045-3 2004 OBJECTIVES: The purpose of this study was to investigate the gelatinolytic activity in human osteosarcoma cells stimulated with interleukin-1alpha (IL-1alpha) or Porphyromonas gingivalis in the absence or presence of SB203580 (p38 inhibitor), U0126 [mitogen-activated protein kinase kinase (MEK) inhibitor], and LY294002 [phosphatidylinositaol 3-kinase (PI3K) inhibitor]. SB 203580 217-225 interleukin 1 alpha Homo sapiens 148-157 15102045-8 2004 In addition, SB203580, U0126, and LY294002 significantly reduced the IL-1alpha or P. gingivalis-stimulated MMP-9 production, respectively (p < 0.05). SB 203580 13-21 interleukin 1 alpha Homo sapiens 69-78 14631115-6 2003 Recombinant IL-1alpha upregulated the expression of both MMP-9 and -13, and the induction of MMP-13 but not MMP-9 could be inhibited by SB203580, an inhibitor of p38. SB 203580 136-144 interleukin 1 alpha Homo sapiens 12-21 14631115-7 2003 Similarly, in primarily cultured human liver MFs, upregulation of MMP-1 by IL-1alpha was also shown to be inhibited by SB203580. SB 203580 119-127 interleukin 1 alpha Homo sapiens 75-84 12502184-2 2002 We found that the inhibitory properties of IL-1 on STAT signalling cascade in human hepatoma HepG2 cells are considerably decreased not only in the presence of MAP kinase inhibitors SB203580 and PD98059 but also by some antioxidants (N-acetyl cysteine and pyrrolidine dithiocarbamate) and by anti-inflammatory cytokine IL-4. SB 203580 182-190 interleukin 1 alpha Homo sapiens 43-47 12020969-4 2002 Treatment with SB203580, a specific inhibitor of p38 mitogen-activated protein kinases (MAPK), potently inhibited IL-1-mediated induction of iNOS and TNFalpha in cultures of human fetal astrocytes. SB 203580 15-23 interleukin 1 alpha Homo sapiens 114-118 11546664-5 2001 SB-203580 treatment enhanced IL-1 alpha-induced MEK, p42/44(mapk), and cPLA(2)alpha phosphorylation but reduced thrombin-stimulated MEK and p42/44(mapk) activation. SB 203580 0-9 interleukin 1 alpha Homo sapiens 29-39 10586114-7 1999 The IL-1-enhanced IL-6 protein secretion was strongly reduced by SB203580 and PD98059. SB 203580 65-73 interleukin 1 alpha Homo sapiens 4-8 11315998-9 2001 Moreover, SB203580, a specific inhibitor of p38 mitogen-activated protein kinase (MAPK), and PD-98059, a specific inhibitor of MAPK kinase (MEKK), also reduced IL-1alpha and RhoA expression in Ap cells. SB 203580 10-18 interleukin 1 alpha Homo sapiens 160-169 11238627-5 2001 Likewise, SB203580 partially prevented the up-regulation of IL-1alpha, IL-1beta, IL-lRa, and TNF-alpha mRNA upon stimulation with LPS and TNF-alpha, as well as the release of bioactive TNF-alpha induced by LPS. SB 203580 10-18 interleukin 1 alpha Homo sapiens 60-69 11367542-3 2001 We used two specific inhibitors, SB203580 which selectively inhibits p38 MAP kinase and LY294002 which inhibits PI3-kinase, respectively, to explore the involvement of these kinases in the IL-1-induced NF-kappa B activation, using a human glioblastoma cell line, T98G. SB 203580 33-41 interleukin 1 alpha Homo sapiens 189-193 11367542-7 2001 While IL-1 induced-AP-1 activation was moderate, both LY294002 and SB203580 suppressed IL-1-induced AP-1 activation. SB 203580 67-75 interleukin 1 alpha Homo sapiens 87-91 10606930-5 2000 SB 203580 inhibited p38 MAP kinase activity and RANTES and GM-CSF production by TNF alpha-, IL-1 alpha- or PAF-stimulated human BECs. SB 203580 0-9 interleukin 1 alpha Homo sapiens 92-102 10586114-2 1999 The IL-3- and IL-1-mediated proliferation were both inhibited by the specific p38 and MEK1 inhibitors SB203580 and PD98059, respectively. SB 203580 102-110 interleukin 1 alpha Homo sapiens 14-18 10400419-8 1999 In contrast, PD98059, a specific inhibitor of the ERK pathway, counteracted the suppressive effects of SB203580 and IL-1 on the apoptotic process indicating that the protective effect of SB203580 and IL-1 might be the result of a shift in the balance between the ERK1/2 and p38/JNK route. SB 203580 103-111 interleukin 1 alpha Homo sapiens 200-204 10400419-8 1999 In contrast, PD98059, a specific inhibitor of the ERK pathway, counteracted the suppressive effects of SB203580 and IL-1 on the apoptotic process indicating that the protective effect of SB203580 and IL-1 might be the result of a shift in the balance between the ERK1/2 and p38/JNK route. SB 203580 187-195 interleukin 1 alpha Homo sapiens 116-120 10445612-4 1999 Inhibition of TNF-alpha- and IL-1alpha-induced p38 MAP kinase activity by SB 203580 inhibited TNF-alpha- and IL-1alpha-induced IL-8 protein production as well as IL-8 messenger ribonucleic acid (mRNA) expression, indicating that SB 203580 was effective at the transcriptional level. SB 203580 229-238 interleukin 1 alpha Homo sapiens 29-38 10358197-3 1999 A selective inhibitor for p38 MAPK, SB203580, almost completely recovered the IL-1-induced growth inhibition in A375-C2-1 cells. SB 203580 36-44 interleukin 1 alpha Homo sapiens 78-82 10358197-4 1999 IL-1-induced IL-6 production was also suppressed by SB203580. SB 203580 52-60 interleukin 1 alpha Homo sapiens 0-4 10358197-7 1999 SB203580 also reversed the IL-1-induced down-regulation of ODC activity and intracellular polyamine levels without affecting ODC mRNA levels in A375-C2-1 cells. SB 203580 0-8 interleukin 1 alpha Homo sapiens 27-31 10445612-4 1999 Inhibition of TNF-alpha- and IL-1alpha-induced p38 MAP kinase activity by SB 203580 inhibited TNF-alpha- and IL-1alpha-induced IL-8 protein production as well as IL-8 messenger ribonucleic acid (mRNA) expression, indicating that SB 203580 was effective at the transcriptional level. SB 203580 74-83 interleukin 1 alpha Homo sapiens 29-38 10445612-4 1999 Inhibition of TNF-alpha- and IL-1alpha-induced p38 MAP kinase activity by SB 203580 inhibited TNF-alpha- and IL-1alpha-induced IL-8 protein production as well as IL-8 messenger ribonucleic acid (mRNA) expression, indicating that SB 203580 was effective at the transcriptional level. SB 203580 74-83 interleukin 1 alpha Homo sapiens 109-118 10445612-4 1999 Inhibition of TNF-alpha- and IL-1alpha-induced p38 MAP kinase activity by SB 203580 inhibited TNF-alpha- and IL-1alpha-induced IL-8 protein production as well as IL-8 messenger ribonucleic acid (mRNA) expression, indicating that SB 203580 was effective at the transcriptional level. SB 203580 229-238 interleukin 1 alpha Homo sapiens 109-118 10385244-10 1999 MK-571 mediated upregulation of IL-6 in the presence of IL-1 was partially attenuated by SB203580 and PD98059. SB 203580 89-97 interleukin 1 alpha Homo sapiens 56-60 7487926-2 1995 Stimulation by IL1 and anisomycin was prevented by SB 203580, a specific inhibitor of the mitogen-activated protein (MAP) kinase homologue termed "re-activating kinase" [RK; also known as p38, p40 and CSBP (cytokine synthesis anti-inflammatory-drug-binding protein)], but was unaffected by PD 98059, a specific inhibitor of the activation of the classical MAP kinase pathway. SB 203580 51-60 interleukin 1 alpha Homo sapiens 15-18 9867839-2 1999 We have previously shown that the pyridinyl imidazole SB 203580, which inhibits it, blocks the interleukin-1 induction of cyclooxygenase-2 (COX-2) and matrix metalloproteinase 1 and 3 mRNAs in fibroblasts. SB 203580 54-63 interleukin 1 alpha Homo sapiens 95-108 9849881-2 1998 SB 203580, an inhibitor of p38 MAPK, in the range 0.1-1 microM inhibited IL-1-stimulated PGE2 (but not arachidonic acid) release and this was associated with inhibition of induction of COX-2 protein and mRNA. SB 203580 0-9 interleukin 1 alpha Homo sapiens 73-77 9648711-6 1998 The specific p38 MAP kinase inhibitor, SB 203580, completely inhibited TNF-alpha-, IL-1alpha-, or PAF-induced IL-8 protein and mRNA expression in BECs. SB 203580 39-48 interleukin 1 alpha Homo sapiens 83-92 32258036-8 2020 The phosphorylation of NR4A1 was increased in human osteoarthritis cartilage, and p38 inhibitor SB203580, JNK inhibitor SP600125 and ERK inhibitor FR180204 could significantly inhibited IL-1beta induced NR4A1 phosphorylation. SB 203580 96-104 interleukin 1 alpha Homo sapiens 186-194 7750577-0 1995 SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. SB 203580 0-9 interleukin 1 alpha Homo sapiens 105-118 7750577-3 1995 We now show that one of these compounds (SB 203580) inhibits RK in vitro (IC50 = 0.6 microM), suppresses the activation of MAPKAP kinase-2 and prevents the phosphorylation of heat shock protein (HSP) 27 in response to interleukin-1, cellular stresses and bacterial endotoxin in vivo. SB 203580 41-50 interleukin 1 alpha Homo sapiens 218-231 35352794-10 2022 Furthermore, p38 inhibitor SB203580 inhibited the production and secretion of TNF-alpha, IL-1beta and IL-8 in THP-1 cells treated with LPS. SB 203580 27-35 interleukin 1 alpha Homo sapiens 89-97